EGFR and head and neck neoplasm: Multiple clinical trials led by Rosenthal and colleagues have successfully demonstrated the use of Cetuximab and Panitumumab (anti-EGFR monoclonal antibodies) conjugated to IRDye800CW for surgical resection of head and neck tumors, 95% of which overexpress EGFR (12).